Affinity Asset Advisors »

Eli Lilly & Co. shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Eli Lilly & Co. (LLY) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Eli Lilly & Co.

Tip: Access up to 7 years of quarterly data

All positions including Eli Lilly & Co. held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Eli Lilly & Co. by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2026-06-30 $24M 20k 1199.43
2022-06-30 $9.7M 30k 324.23

More positions owned by Affinity Asset Advisors

Roivant Sciences SHS (ROIV)
Apogee Therapeutics (APGE)
Spyre Therapeutics Com New (SYRE)
Xenon Pharmaceuticals (XENE)
Erasca (ERAS)
Alkermes SHS (ALKS)
Insmed Com Par $.01 (INSM)
Moderna Put Option (MRNA)
Praxis Precision Medicines I Com New (PRAX)
Oruka Therapeutics (ORKA)
Anaptysbio Inc Common (ANAB)
Avalo Therapeutics Com New (AVTX)
Cytokinetics Com New (CYTK)
Revolution Medicines (RVMD)
Abivax Sa Sponsored Ads (ABVX)

View all positions for Affinity Asset Advisors

Top funds holding Eli Lilly & Co.

Lilly Endowment
BlackRock
Vanguard Capital Management
Pnc Financial Services
State Street Corporation
FMR
Capital Research Global Investors
Vanguard Portfolio Management
Geode Capital Management
Capital World Investors
Morgan Stanley
T. Rowe Price Associates
Jpmorgan Chase & Co
UBS Group
Norges Bank Investment Management

View all funds holding Eli Lilly & Co.